文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

氯胺酮与依托咪酯用于危重症成人气管插管

Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults.
PubMed 文献 · N Engl J Med · 2025-12-09
一句话结论危重症成人气管插管诱导时,氯胺酮较依托咪酯未显著降低28天院内死亡,但插管期间心血管崩溃发生率更高。

该随机试验在美国14个急诊科和ICU纳入2365例接受气管插管的危重症成人,比较氯胺酮与依托咪酯诱导麻醉。主要终点28天院内死亡在氯胺酮组为28.1%,依托咪酯组为29.1%,校正后风险差-0.8个百分点(95%CI -4.5至2.9;P=0.65),无显著差异。次要终点插管期间心血管崩溃在氯胺酮组为22.1%,依托咪酯组为17.0%,风险差5.1个百分点(95%CI 1.9至8.3)。作者结论认为氯胺酮未较依托咪酯显著降低28天院内死亡。

要点

  • 危重症成人气管插管诱导:氯胺酮组28天院内死亡28.1%(330/1173) vs 依托咪酯组29.1%(345/1186),校正后风险差-0.8个百分点(95%CI -4.5至2.9;P=0.65),无显著差异。
  • 插管期间心血管崩溃:氯胺酮组22.1%(260/1176) vs 依托咪酯组17.0%(202/1189),风险差5.1个百分点(95%CI 1.9至8.3)。
  • 预设安全性结局在两组间相似。
  • 研究纳入美国14个急诊科和ICU的危重症成人,随机接受氯胺酮或依托咪酯诱导。

适用人群与场景

  • 美国14个急诊科和ICU中接受气管插管的危重症成人。

研究设计与关键结果

  • 随机试验,共2365例患者纳入试验人群,氯胺酮组1176例,依托咪酯组1189例。
  • 主要终点28天院内死亡:氯胺酮组330/1173(28.1%) vs 依托咪酯组345/1186(29.1%),校正试验中心后的风险差-0.8个百分点(95%CI -4.5至2.9;P=0.65)。
  • 次要终点插管期间心血管崩溃(收缩压低于65 mm Hg、接受新或增加剂量的血管升压药、或心脏骤停):氯胺酮组260/1176(22.1%) vs 依托咪酯组202/1189(17.0%),风险差5.1个百分点(95%CI 1.9至8.3)。
  • 预设安全性结局在两组间相似。

证据类型、等级与局限

  • 证据类型:随机试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在危重症成人气管插管中,使用氯胺酮诱导麻醉未较依托咪酯显著降低28天院内死亡发生率。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: For critically ill adults undergoing tracheal intubation, observational studies suggest that the use of etomidate to induce anesthesia may increase the risk of death. Whether the use of ketamine rather than etomidate decreases the risk of death is uncertain.

METHODS: In a randomized trial conducted in 14 emergency departments and intensive care units in the United States, we randomly assigned critically ill adults who were undergoing tracheal intubation to receive ketamine or etomidate for the induction of anesthesia. The primary outcome was in-hospital death from any cause by day 28. The secondary outcome was cardiovascular collapse during intubation, defined by the occurrence of a systolic blood pressure below 65 mm Hg, receipt of a new or increased dose of vasopressors, or cardiac arrest.

RESULTS: A total of 2365 patients underwent randomization and were included in the trial population; 1176 were assigned to the ketamine group and 1189 to the etomidate group. In-hospital death by day 28 occurred in 330 of 1173 patients (28.1%) in the ketamine group and in 345 of 1186 patients (29.1%) in the etomidate group (risk difference adjusted for trial site, -0.8 percentage points; 95% confidence interval [CI], -4.5 to 2.9; P = 0.65). Cardiovascular collapse during intubation occurred in 260 of 1176 patients (22.1%) in the ketamine group and in 202 of 1189 patients (17.0%) in the etomidate group (risk difference, 5.1 percentage points; 95% CI, 1.9 to 8.3). Prespecified safety outcomes were similar in the two groups.

CONCLUSIONS: Among critically ill adults undergoing tracheal intubation, the use of ketamine to induce anesthesia did not result in a significantly lower incidence of in-hospital death by day 28 than etomidate. (Funded by the Patient-Centered Outcomes Research Institute and others; RSI ClinicalTrials.gov number, NCT05277896.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Casey JD, Seitz KP, Driver BE, et al. Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults. N Engl J Med. 2025. PMID: 41369227. doi:10.1056/NEJMoa2511420

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。